Significant differences have been demonstrated in the risk of incident type 2 diabetes (T2D) and T2D-related complications by patient race. Because the presence of comorbidities can directly impact a physician’s selection of antidiabetic therapy, the current study sought to quantify differences in prevalence of diabetes-related comorbidities by race and cardiovascular disease (CVD) status in a large U.S. cohort. We conducted a retrospective study of T2D patients ≥18 years who had ≥1 encounter in the Quintiles Electronic Medical Record database from October 2014 to September 2015, as well as ≥1 year of medical history available. Of the 1,522,526 eligible patients, 54% were female, median age was 65 years, and median HbA1c was 6.7%. The cohort representation by race, and prevalence of comorbidities by CVD status, are shown in the table. Overall, 25% of patients had CVD, but this varied by race from 18.6% to 30.5%. The most prevalent comorbidities for all races included hypertension, hyperlipidemia, overweight/obesity, chronic kidney disease, neuropathy and heart failure, with rates generally higher among patients with CVD. Foot infections were also common for those with CVD across subgroups, but especially for Asian patients with CVD (36.9%).

In conclusion, patients with T2D and CVD had higher rates of common comorbidities vs. those without CVD, but rates varied by racial subgroups.

K. Iglay: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. H. Hannachi: Employee; Self; Merck & Co., Inc. S.S. Engel: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc.. X. Li: None. D.J. O'Connell: None. L.M. Moore: None. S. Rajpathak: Employee; Self; Merck & Co., Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at